Assessing the net financial benefits of employing digital endpoints in clinical trials
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Joseph A DiMasi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Endpoint Determination. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In the last few decades, developers of new drugs, biologics, and devices have increasingly leveraged digital health technologies (DHTs) to assess clinical trial digital endpoints. To our knowledge, a comprehensive assessment of the financial net benefits of digital endpoints in clinical trials has not been conducted. We obtained data from the Digital Medicine Society (DiMe) Library of Digital Endpoints and the US clinical trials registry, ClinicalTrials.gov . The benefit metrics are changes in trial phase duration and enrollment associated with the use of digital endpoints. The cost metric was obtained from an industry survey of the costs of including digital endpoints in clinical trials. We developed an expected net present value (eNPV) model of the cash flows for new drug development and commercialization to assess financial value. The value measure is the increment in eNPV that occurs when digital endpoints are employed. We also calculated a return on investment (ROI) as the ratio of the estimated increment in eNPV to the mean digital endpoint implementation cost. For phase II trials, the increase in eNPV varied from $2.2 million to $3.3 million, with ROIs between 32% and 48% per indication. The net benefits were substantially higher for phase III trials, with the increase in eNPV varying from $27 million to $40 million, with ROIs that were four to six times the investment. The use of digital endpoints in clinical trials can provide substantial extra value to sponsors developing new drugs, with high ROIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA.
- Digital Medicine Society, Boston, Massachusetts, USA.
- F. Hoffmann-La Roche Ltd., Basel, Switzerland.
- Bayer AG, Reading, UK.
- Takeda Pharmaceutical Company Limited, Zurich, Switzerland.
- UCB S.A., Monheim, Germany.
ORCID-Profile: Joseph A DiMasi, Sarah Valentine, Upinder Grewal, Daniel Karlin, Bert Hartog
Zitieren
APA
DiMasi, J. A., Dirks, A., Smith, Z., Valentine, S., Goldsack, J. C., Metcalfe, T., Grewal, U., Leyens, L., Conradi, U., Karlin, D., Maloney, L., Getz, K. A., & Hartog, B. (2024). Assessing the net financial benefits of employing digital endpoints in clinical trials. Clinical and Translational Science. https://doi.org/10.1111/cts.13902
Vancouver
DiMasi JA, Dirks A, Smith Z, Valentine S, Goldsack JC, Metcalfe T, et al. Assessing the net financial benefits of employing digital endpoints in clinical trials. Clinical and Translational Science. 2024. doi:10.1111/cts.13902
BibTeX
@article{DiMasi2024,
author = {DiMasi, Joseph A and Dirks, Abigail and Smith, Zachary and Valentine, Sarah and Goldsack, Jennifer C and Metcalfe, Thomas and Grewal, Upinder and Leyens, Lada and Conradi, Ute and Karlin, Daniel and Maloney, Lesley and Getz, Kenneth A and Hartog, Bert},
title = {Assessing the net financial benefits of employing digital endpoints in clinical trials},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13902}
}
EUVIMED